You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
復宏漢霖(02696.HK)獲授HCB101許可 首付款1,000萬美元
阿思達克 07-01 15:33
復宏漢霖(02696.HK)公布,與FBD Biologics「FBD」訂立許可協議,據此,公司獲授予獨家許可,以於領域(所有人類用途)及許可區域(中國、香港和澳門,東南亞特定國家,以及特定MENA地區國家)開發、生產、商業化或以其他方式利用HCB101和以其作為原料藥的藥品。HCB101能夠以高親和力與CD47結合,增強巨噬細胞對腫瘤細胞的吞噬作用。目前處於1b/2a期臨床試驗中。 公司須向FBD支付︰首付款1,000萬美元;開發及監管里程碑付款合計不超過4,900萬美元;商業里程碑付款合計不超過1.43億美元;及以年度淨銷售額一至兩位數百分比計的特許權使用費。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account